GOALS
- Improved knowledge of current mechanisms of action of immunotherapeutic agents and how they apply to the treatment of RCC in terms of rationale.
- Increased confidence in use of immunotherapies for RCC and utilization of relevant combination regimens in appropriate patients as part of their overall treatment to improve outcomes in patients with RCC.
- Improved understanding of the need to identify the range of irAEs, and improved knowledge of how irAEs differ from side effects associated with traditional chemotherapy.
TARGET AUDIENCE
This activity is intended for medical oncologists, urologist oncologists, surgeons and other healthcare professionals involved in the care or treatment of patients with RCC such as oncology nurses, nurse practitioners, and physician assistants.
EDUCATIONAL METHODS
Lecture/Didactic; Case study; Panel discussion; Pre-/Post-Test; Other: Online toolkit may use polling questions
EDUCATIONAL OBJECTIVES
At the conclusion of this educational activity, the participant should be able to:
- Compare and contrast evidence from immunotherapy clinical trials to assess how newly approved and emerging immunotherapies improve treatment of RCC, including combination anti-VEGF and immunotherapeutic platforms (Knowledge, Competence)
- Discuss clinical factors when immunotherapy or combination immunotherapy should be considered as a treatment option for patients with RCC, such as patient selection, optimal drug combinations, and treatment sequence (Knowledge, Competence, Performance)
- Review clinical strategies for the early detection and management of immunotherapy and immunotherapy combination related adverse events in RCC patients and management plans to help mitigate them (Knowledge, Competence, Performance)
ACCREDITATION/CREDIT DESIGNATION
The University of Texas MD Anderson Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Texas MD Anderson Cancer Center designates this internet enduring material activity for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CME CERTIFICATES AND ATTENDANCE CERTIFICATES
Certificates awarding AMA PRA Category 1 Credit™ or certificates documenting participation will be issued immediately to participants when an individual completes the post-test and evaluation.
Non-Physicians will receive a certificate of participation in accordance with state nursing boards, specialty societies, or other professional associations.
COMMERCIAL SUPPORT
Supported by an educational grant from Pfizer and EMD Serono.
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER DISCLOSURE POLICY FOR PROGRAM CHAIRS, PLANNING COMMITTEE MEMBERS, TEACHERS, OR AUTHORS AND CME ACTIVITY REVIEWERS
The Accreditation Council for Continuing Medical Education has announced standards and guidelines to insure that individuals participating in CME activities are aware of program chair(s), planning committee members, faculty/teacher/ authors, CME activity reviewer’s relationships with commercial interests that could potentially affect the information presented. The University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest.
The University of Texas MD Anderson Cancer Center has, through a formal review process, resolved all conflicts of interest prior to this activity. For information on this process, please contact CME/Conference Management at (713) 792-5357.
The following Faculty, Program Planning Committee Members and CME Activity Reviewers/Approvers have financial interests, arrangements or affiliations with the manufacturer of any product or devices to be discussed, or who may financially support this CME activity, as indicated below. An asterisk (*) indicates that the faculty’s presentation will include discussion of investigational or off-label uses of a product.
| FACULTY | COMMERCIAL INTEREST | |
|---|
| David F. McDermott, MD | Grant or research support: Bristol Myers Squibb, Merck, Genetech, Pfizer, Exelixis, X4 Pharmaceuticals, Alkermes, Inc.; Paid consultant: Bristol Myers Squibb, Pfizer, Merck, Alkernes, Inc., EMD Serono, Eli Lilly and Company | |
| Robert J. Motzer, MD | Grant or research support: Pfizer, Eisai, Exelixis, Genetech/Roche, Bristol Myers Squibb; Paid consultant: Pfizer, Merck, Novartis, Genetech/Roche, Eli Lilly and Company | |
| Brian I. Rini, MD, FACP | Grant or research support: Pfizer, Bristol Myers Squibb, Merck, Roche, AstraZeneca; Paid consultant: Pfizer, Bristol Myers Squibb, Merck, Roche, AstraZeneca | |
| Nizar M. Tannir, MD, FACP | Grant or research support: Bristol Myers Squibb, Pfizer, Nekkar Therapeutics, Exelisis Inc., Calithera Bioscience; Paid consultant: Bristol Myers Squibb, Pfizer, Nekkar Therapeutics, Exelisis Inc., Eisai Medical Research, Eli Lilly Oncorena; Honoraria: Bristol Myers Squibb, Pfizer, Nekkar Therapeutics, Exelisis Inc., Eisai Medical Research, Eli Lilly Oncorena | |
| PLANNING COMMITTEE MEMBERS | COMMERCIAL INTEREST | |
|---|
| Amanda Kaczerski, MS, CHCP | Employment: Celgene (Celgene id Amandas’ husband’s employer and this has no influence on any content that has been developed in collaboration between ACHL and MD And) | |
| Nizar M. Tannir, MD, FACP | Grant or research support: Bristol Myers Squibb, Pfizer, Nekkar Therapeutics, Exelisis Inc., Calithera Bioscience; Paid consultant: Bristol Myers Squibb, Pfizer, Nekkar Therapeutics, Exelisis Inc., Eisai Medical Research, Eli Lilly and Company, Oncorena; Honoraria: Bristol Myers Squibb, Pfizer, Nekkar Therapeutics, Exelisis Inc., Eisai Medical Research, Eli Lilly and Company, Oncorena | |
The following Faculty/Program Planning Committee Members and CME Activity Reviewers/Approvers HAVE INDICATED THEY HAVE NO FINANCIAL INTERESTS, arrangements or affiliations with the manufacturer of any product or devices to be discussed, or who may financial support this CME activity. An asterisk (*) indicates that the faculty’s presentation will include discussion of investigational or off-label uses of a product.
| PLANNING COMMITTEE MEMBERS |
|---|
| Angelic Castillo | Katlyn Cooper | Arman Nabatiyan, PhD |
| CME ACTIVITY REVIEWERS/APPROVERS |
|---|
| Diane C. Bodurka, MD, BS, MPH (approver) | Anis Rashid, MD |
| Peter Norman, MD | Suresh Reddy, MD |
Academic Detailing
Overview
